{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T23:40:25Z","timestamp":1740958825769,"version":"3.38.0"},"reference-count":39,"publisher":"Japanese Pharmacological Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1254\/jphs.10311fp","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T05:20:15Z","timestamp":1298524815000},"page":"374-382","source":"Crossref","is-referenced-by-count":10,"title":["Comparative Characterization of Lung Muscarinic Receptor Binding After Intratracheal Administration of Tiotropium, Ipratropium, and Glycopyrrolate"],"prefix":"10.1254","volume":"115","author":[{"given":"Masaki","family":"Ogoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Niiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadatsura","family":"Koshika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"unstructured":"1 Barnes PJ. Neural control of human airways in health and disease. Am Rev Respir Dis. 1986;134:1289–1314.","key":"1"},{"doi-asserted-by":"crossref","unstructured":"2 Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverly P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–575.","key":"2","DOI":"10.1164\/rccm.200703-456SO"},{"doi-asserted-by":"crossref","unstructured":"3 Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstructive due to emphysema. N Engl J Med. 1984;311:421–425.","key":"3","DOI":"10.1056\/NEJM198408163110701"},{"doi-asserted-by":"publisher","key":"4","DOI":"10.1186\/1465-9921-7-73"},{"doi-asserted-by":"publisher","key":"5","DOI":"10.1183\/09031936.02.00238702"},{"doi-asserted-by":"publisher","key":"6","DOI":"10.1056\/NEJMoa0805800"},{"doi-asserted-by":"crossref","unstructured":"7 Casaburi R. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127:809–817.","key":"7","DOI":"10.1378\/chest.127.3.809"},{"doi-asserted-by":"crossref","unstructured":"8 Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Inter Med. 2005;143:317–326.","key":"8","DOI":"10.7326\/0003-4819-143-5-200509060-00007"},{"doi-asserted-by":"crossref","unstructured":"9 Cramer JA, Bradey-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J. 2007;14:25–29.","key":"9","DOI":"10.1155\/2007\/161652"},{"doi-asserted-by":"crossref","unstructured":"10 Joos GF. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Expert Opin Investig Drug. 2010;19:257–264.","key":"10","DOI":"10.1517\/13543780903505084"},{"doi-asserted-by":"crossref","unstructured":"11 Josep LH. Tiotropium bromide: an updata. Open Respir Med J. 2009;3:43–52.","key":"11","DOI":"10.2174\/1874306400903010043"},{"doi-asserted-by":"publisher","key":"12","DOI":"10.1016\/S0024-3205(98)00588-8"},{"doi-asserted-by":"crossref","unstructured":"13 Braun SR, Levy SF. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med. 1991;91:28S–32S.","key":"13","DOI":"10.1016\/0002-9343(91)90259-Z"},{"unstructured":"14 Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al, editors, Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 141–160.","key":"14"},{"doi-asserted-by":"crossref","unstructured":"15 Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest. 1996;110:62–70.","key":"15","DOI":"10.1378\/chest.110.1.62"},{"doi-asserted-by":"crossref","unstructured":"16 Walker IV, Kaiser FB, Kowal DL, Suratt PM. Prolonged effect of inhaled glycopyrrolate in asthma. Chest. 1987;91:49–51.","key":"16","DOI":"10.1378\/chest.91.1.49"},{"doi-asserted-by":"crossref","unstructured":"17 Schroeckenstein DC, Bush RK, Chervinsky P, Busse WW. Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J Allergy Clin Immunol. 1988;82:115–119.","key":"17","DOI":"10.1016\/0091-6749(88)90060-7"},{"doi-asserted-by":"crossref","unstructured":"18 Tzelepis G, Komanapolli S, Tyler D, Vega D, Fulambarker A. Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Eur Respir J. 1996;9:100–103.","key":"18","DOI":"10.1183\/09031936.96.09010100"},{"doi-asserted-by":"publisher","key":"19","DOI":"10.1038\/sj.bjp.0702573"},{"doi-asserted-by":"crossref","unstructured":"20 Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther. 2005;27:377–392.","key":"20","DOI":"10.1016\/j.clinthera.2005.04.006"},{"doi-asserted-by":"publisher","key":"21","DOI":"10.1254\/jphs.09R14FM"},{"doi-asserted-by":"publisher","key":"22","DOI":"10.1038\/sj.bjp.0705371"},{"doi-asserted-by":"publisher","key":"23","DOI":"10.1016\/j.lfs.2005.12.049"},{"doi-asserted-by":"publisher","key":"24","DOI":"10.1097\/01.ju.0000138472.16876.8d"},{"doi-asserted-by":"publisher","key":"25","DOI":"10.1038\/sj.bjp.0706184"},{"doi-asserted-by":"publisher","key":"26","DOI":"10.1124\/jpet.105.094508"},{"doi-asserted-by":"publisher","key":"27","DOI":"10.1124\/jpet.108.136390"},{"issue":"1","key":"28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0022-3565(25)32274-3","volume":"215","author":"Yamada S., Yamamura H.I., Roeske W.","year":"1980","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3565","issn-type":"print"},{"doi-asserted-by":"crossref","unstructured":"29 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;93:265–275.","key":"29","DOI":"10.1016\/S0021-9258(19)52451-6"},{"doi-asserted-by":"publisher","key":"30","DOI":"10.1016\/0024-3205(88)90398-0"},{"doi-asserted-by":"publisher","key":"31","DOI":"10.1016\/0163-7258(93)90027-B"},{"doi-asserted-by":"crossref","unstructured":"32 Eglen RM, Reddy H, Watson N, Vhallis RAJ. Muscarinic acetylcholine receptors in smooth muscles. Trends Pharmacol Sci. 1994;15:114–115.","key":"32","DOI":"10.1016\/0165-6147(94)90047-7"},{"doi-asserted-by":"crossref","unstructured":"33 Roffel AF, Elzinga CRS, van Amsterdam RGM, de Zeeuw RA, Zaagsma J. Muscarinic M2<\/SUB> receptors in bovine tracheal smooth muscle: discrepancies between binding and function. Eur J Pharmacol. 1996;153:73–82.","key":"33","DOI":"10.1016\/0014-2999(88)90589-4"},{"doi-asserted-by":"crossref","unstructured":"34 Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:297–304.","key":"34","DOI":"10.1513\/pats.200504-043SR"},{"doi-asserted-by":"publisher","key":"35","DOI":"10.1111\/j.1476-5381.2009.00113.x"},{"doi-asserted-by":"crossref","unstructured":"36 Villeti G, Bergamaschi M, Bassani F, Bolzoni PT, Harrison S, Gigli PM, et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol. 2006;148:291–298.","key":"36","DOI":"10.1038\/sj.bjp.0706724"},{"doi-asserted-by":"publisher","key":"37","DOI":"10.1124\/jpet.109.152470"},{"doi-asserted-by":"crossref","unstructured":"38 Dowling MR, Charlton SJ. Quantifying the association and dissociation rates of unlabelled antagonists at the muscarnic M3<\/SUB> receptors. Br J Pharmacol. 2006;148:927–937.","key":"38","DOI":"10.1038\/sj.bjp.0706819"},{"doi-asserted-by":"crossref","unstructured":"39 Armstrong SR, Briones S, Horger B, Richardson CL, Jaw-Tsai S, Hegde SS. Pharmacological analysis of the interaction of antimuscarinic drugs at M(2) and M(3) muscarinic receptors in vivo using the pithed rat assay. Naunyn Schmiedebergs Arch Pharmacol. 2008;376:341–349.","key":"39","DOI":"10.1007\/s00210-007-0224-0"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T23:16:49Z","timestamp":1740957409000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/115\/3\/115_10311FP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.10311fp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"type":"print","value":"1347-8613"},{"type":"electronic","value":"1347-8648"}],"subject":[],"published":{"date-parts":[[2011]]}}}